Anti‐ovarian carcinoma anti‐T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T‐cells
暂无分享,去创建一个
S. Ménard | D. Mezzanzanica | M. Colnaghi | Delia Mezzanzanica | Sylvie Ménard | Sitvana Canevari | Silvia Mjotti | Screnella M. Pupa | Antonio Lanzavrcchia | Maria I. Colnaghi | S. Canevari | S. Pupa | Silvia Mjotti | Antonio Lanzavrcchia
[1] A. Lanzavecchia,et al. The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.
[2] M. Bevan,et al. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[3] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[4] P. Parham. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. , 1983, Journal of immunology.
[5] R. W. Baldwin,et al. MONOCLONAL ANTIBODIES IN CANCER TREATMENT , 1986, The Lancet.
[6] S. Ménard,et al. Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. , 1985, Journal of the National Cancer Institute.
[7] D. Segal,et al. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies , 1986, The Journal of experimental medicine.
[8] S. Ménard,et al. Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.
[9] C. Milstein,et al. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. , 1984, Immunology today.